title: Patency of paclitaxel-eluting versus bare metal stents long term after implantation in acute ST-segment elevation myocardial infarction.
abstract: Drug-eluting stents effectively inhibit neointimal hyperplasia within the first year, thereby reducing the need for repeat revascularization. However, a delayed pattern of restenosis might be more prominent in drug-eluting stents compared to bare metal stents (BMSs). The extent of restenosis of paclitaxel-eluting stents (PESs) long term after implantation in acute ST-segment elevation myocardial infarction is currently unknown. The present study was designed to evaluate very late luminal loss (VLLL) of PESs used in ST-segment elevation myocardial infarction compared to BMSs. A total of 116 patients (61 with PESs and 55 with BMSs) initially included in the Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) trial and who were free from previous lesion failure underwent angiographic follow-up. Off-line quantitative coronary analysis of the angiogram immediately after stent implantation and at follow-up was performed. The primary end point was VLLL within the stent. The presence of binary restenosis was defined as diameter stenosis >50% as a secondary end point. The mean interval between stent implantation and follow-up was 4.1 ± 0.5 years in both stent groups. In-stent VLLL was 0.12 mm (interquartile range -0.03 to 0.42) in the PES group versus 0.30 mm (interquartile range 0.08 to 0.69) in the BMS group (p = 0.011). In-segment binary restenosis was found in 4 patients (6.6%) with a PES and 6 patients (10.9%) with a BMS (p = 0.40). In conclusion, angiographic follow-up 4 years after implantation in ST-segment elevation myocardial infarction showed that in patients prospectively randomized to PESs or BMSs, VLLL was low in both stent groups. PESs were associated with lower VLLL than BMSs, and the observed rate of binary restenosis was not significantly different between the 2 stent groups.
authors.affiliation: Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. m.a.vink@olvg.nl
authors.forename: Maarten A
authors.initials: MA
authors.lastname: Vink
authors.forename: Ferdinand C
authors.initials: FC
authors.lastname: Van Nooijen
authors.forename: Gerrit J
authors.initials: GJ
authors.lastname: Laarman
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Suttorp
authors.forename: Jan G
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Ton
authors.initials: T
authors.lastname: Slagboom
authors.forename: Mark S
authors.initials: MS
authors.lastname: Patterson
authors.forename: Rene J
authors.initials: RJ
authors.lastname: Van Der Schaaf
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Kiemeneij
authors.forename: Giovanni
authors.initials: G
authors.lastname: Amoroso
authors.forename: Maurits T
authors.initials: MT
authors.lastname: Dirksen
mesh_terms: D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D015607:Stents; D014654:Vascular Patency
chemical_list: D017239:Paclitaxel